Navigation Links
US Capital Global Securities Launches $15 Million Equity Investment in Clinical Stage Pharmaceutical Company
Date:4/8/2019

US Capital Global Securities, an affiliate of US Capital Global, is offering to accredited investors a $15 million preferred equity investment in the privately held pharmaceutical company, S1 Biopharma (“S1”).

S1 has a pipeline of drugs targeted at sexual dysfunction. Its leading drug, Lorexys, is targeted at female hypoactive sexual dysfunction disorder and is ready to begin phase 2b trials. In phase 2a trials, Lorexys had strong results relative to competing drugs; one of which was sold for over $1B. The company intends to use proceeds from the raise to fund phase 2b trials for Lorexys.

Headquartered in San Francisco, US Capital Global is a full-service private financial group with an established track record in investment banking and capital raise services. Its registered broker-dealer affiliate, US Capital Global Securities, LLC, is acting as the exclusive placement agent for the equity raise for S1 Biopharma.

“We are excited to have US Capital Global Securities’ experienced team assist us in raising this Series A round of funding, which will enable S1 to complete phase 2b trials” said Nick Sitchon, CEO at S1 Biopharma. “US Capital Global’s support and expertise will enable S1 to reach a critical milestone on the path to FDA approval.”

“It has been a pleasure serving S1 as its lead financial advisor,” said Charles Towle, CEO at US Capital Global Securities. “Our shared enthusiasm for Lorexys’ strong phase 2a data was a key determinant in accepting this engagement. With US Capital Global Securities’ financial advisory and capital raise services, S1 is in a good position to advance its clinical trials. The opportunity to participate in this $15 million preferred equity investment is now open to eligible investors.

About S1 Biopharma

S1 Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the treatment of sexual dysfunction in both women and men. The company’s development programs include first-in-class non-hormonal therapies designed to treat diminished sexual desire by restoring the natural balance of key neurotransmitters in the brain. The company’s lead product candidate, Lorexys, is currently positioned to advance to a Phase 2b clinical trial for the treatment of hypoactive sexual desire disorder (HSDD) in women. For more information, visit http://www.s1biopharma.com or follow S1 Biopharma on Facebook or Twitter (@s1biopharma).

About US Capital Global

US Capital Global Securities, LLC is the FINRA-licensed broker dealer division of US Capital Global that acts as placement agent for growth-stage companies, projects, and investment funds. Since 1998, the US Capital Global team has been committed to providing small and lower middle market businesses and investors with sophisticated debt, equity, and investment opportunities usually available only to larger middle market companies and institutional investors. US Capital Global manages direct investment funds and provides wealth management and capital raise services.

To learn more about US Capital Global Securities or this investment opportunity, email Charles Towle, Managing Partner, at charles@uscgs.com or call (415) 889-1010.

Read the full story at https://www.prweb.com/releases/us_capital_global_securities_launches_15_million_equity_investment_in_clinical_stage_pharmaceutical_company/prweb16226087.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
2. RXi Pharmaceuticals Announces Application for NASDAQ Capital Market Listing and Reverse Stock Split
3. Capitalizing on Opportunities in Cord Blood Industry Growth (2013 Version)
4. GW Pharmaceuticals to Present at the 2013 Aegis Capital Healthcare Conference
5. Regado Biosciences, Inc. to Present at Aegis Capital Vegas Healthcare Conference
6. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
7. S&P Capital IQ to Share Its Views on the Biotech Bull Market During the Next "ETF Analyst Hour"
8. Foundation Venture Capital Group Portfolio Company Identifies FRY Gene As Breast Cancer Susceptibility Suppressor
9. TVM Capital Group Announces Two-pronged Global Investment Strategy with Renewed MENA Focus
10. UCLA Venture Capital Fund Selects KYTHERA Biopharmaceuticals CEO Keith Leonard for First Annual Entrepreneurial Achievement Award
11. Soligenix Announces Initial $600,000 Investment and up to $10.6 Million Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2019)... ... 2019 , ... Personalized Stem Cells, Inc (“PSC”), a human adipose-derived ... for use of a person’s own adipose-derived stem cells to treat their osteoarthritis. The ... This IND is the first of several planned clinical trials which will enable ...
(Date:6/11/2019)... (PRWEB) , ... June 11, 2019 , ... ... engagement, and Carilion Clinic, a national leader in opioid treatment, announced today they ... care. , Mytonomy recently deployed its virtual care platform at the ...
(Date:5/31/2019)... City, California (PRWEB) , ... ... ... allowance of our patent applications from the USPTO providing proprietary interest to ... AND METHOD FOR SLEEP DISORDER DIAGNOSIS AND TREATMENT… extends Somnology’s IP rights ...
(Date:5/21/2019)... ... May 21, 2019 , ... ... today officially opened the inaugural Africa Brewing Conference dedicated to sharing brewing knowledge, ... Africa. The event, which is supported through a partnership with “Ethiopia Invest”, will ...
Breaking Biology Technology:
(Date:6/18/2019)... BEACH, Calif. (PRWEB) , ... June 18, 2019 ... ... of multi-GPU deep learning cloud solutions, today introduced Data Science Workstations-as-a-Service as part ... science workstation hardware from BOXX Technologies, Cirrascale Data Science Workstations feature NVIDIA® Quadro ...
(Date:6/14/2019)... ... 2019 , ... Molecular diagnostics segment is the fastest-growing segment within the global ... Major segments that are expected to drive the growth are infectious diseases, cancer, and ... in Kalorama’s The World Molecular Diagnostics Market, 8th Edition . , The discovery ...
(Date:6/11/2019)... ... June 12, 2019 , ... With a ... plans to leverage the Geneious Biologics platform as a premium hub for bioinformatics ... at Abveris, says: “The Geneious team has done an excellent job accommodating our ...
Breaking Biology News(10 mins):